Compare Comfort Systems USA Inc (FIX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs Twist Bioscience Corp — how do they compare? Comfort Systems USA Inc trades at $1,737 (market cap $60.06B), while Twist Bioscience Corp trades at $154.2 (market cap $10.08B). The key difference: Comfort Systems USA Inc is far larger — about 6× Twist Bioscience Corp's market cap, and Comfort Systems USA Inc pays a 0.21% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 41 Days and Twist Bioscience Corp for 27 Days on average.
| FIX | TWST | |
|---|---|---|
Market Cap | $60.06B | $10.08B |
Volume | 371,896 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $2.07K | $205.00 |
52-Week Low | $790.72 | $25.45 |
Typical Hold Time | 41 Days | 27 Days |
Enterprise Value | $58.53B | $10.01B |
Dividend Yield | 0.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,741.36, down 4.21% today but maintains strong technical momentum with bullish moving averages and support at $1,712. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $12.53 vs. $10.45, while revenue growth accelerates from $9.1B in 2025 to $11.2B in 2026. Recent acquisition of Hunt Electric adds $250M in annual revenue, positioning FIX to capitalize on data center and infrastructure demand.
FIX presents a compelling growth opportunity with 55.56% analyst buy ratings and a $2,080 consensus price target offering 19% upside. Key risks include execution challenges in integrating acquisitions and potential margin pressure from rising costs. The stock's premium valuation (P/E 42) requires sustained earnings growth, but strong ROE (55.29%) and expanding data center backlog support the bullish case.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
